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Background: To identify the incidence rate of spontaneous dyskinesia (SD) and tardive dyskinesia (TD) in a general
population and to examine the association between dykinesia and potential risk factors (exposure to
metoclopramide [MCP], antipsychotic drugs, and history of diabetes and psychoses).
Methods: A retrospective cohort study was conducted for the years 2001 through 2010, based on medical claims
data from the Deseret Mutual Benefit Administrators (DMBA).
Results: Thirty-four cases of TD and 229 cases of SD were identified. The incidence rate of TD among persons
previously prescribed an antipsychotic or metoclopramide (MCP) (per 1,000) was 4.6 (1.6-7.7) for those with
antipsychotic drug use only, 8.5 (4.8-12.2) for those with MCP use only, and 15.0 (2.0-28.1) for those with both
antipsychotic and MCP use. In the general population, the incidence rate (per 100,000 person-years) of TD was 4.3
and of probable SD was 28.7. The incidence rates of TD and SD increased with age and were greater for females.
Those with diabetes or psychoses had almost a 3-fold greater risk of TD than those without either of these diseases.
Persons with schizophrenia had 31.2 times increased risk of TD than those without the disease. Positive associations
also existed between the selected diseases and the incidence rate of probable SD, with persons with schizophrenia
having 4.4 times greater risk of SD than those without the disease.
Conclusions: SD and TD are rare in this general population. Diabetes, psychoses, and especially schizophrenia are
positively associated with SD and TD. A higher proportion of those with SD present with spasm of the eyelid
muscles (blepharospasm) compared more with the TD cases who present more with orofacial muscular
problems.
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The introduction of chlorpromazine and other anti-
psychotic drugs into medical practice in the 1950’s revo-
lutionized the treatment of schizophrenia. However,
these drugs were not without some unanticipated side
effects. The most common were increased occurrence
of neuromuscular problems, especially Parkinson’s like
muscle rigidity. A less common side effect was dyskinesia.
Dyskinesia manifests its presence as abnormal involuntary,
repetitive, persistent, stereotypic movements usually of the
facial muscles but can also involve other muscle groups in-
cluding the extremities and the torso [1]. When this condi-
tion occurs sometime after the initiation of antipsychotic* Correspondence: Ray_Merrill@byu.edu
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reproduction in any medium, provided the ordrugs that damage GABAergic medium spiny neurons
(MSNs), it is referred to as tardive (or delayed) dyskinesia
(TD) [2]. New research has distinguished MSNs as the first
station in the corticostriato-thalamo-cortical circuit that
regulates the amplitude and velocity of movements [2].
Studies have identified an elevated risk of dys-
kinesia among schizophrenics exposed to first- and
second-generation neuroleptic (antipsychotic) drugs,
with second-generation neuroleptics posing a lower risk
[3-7]. First-generation antipsychotic drugs are more
likely to cause movement disorders because they bind
tightly to dopaminergic neuroreceptors (e.g., haloperi-
dol). Nevertheless, some of these earlier developed drugs
are still in use today. There is currently little information
as to the incidence rate of dyskinesia among those with-
out an underlying psychosis. Other drugs, especiallytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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esis, were also claimed to increase the incidence of TD.
The common pathway for these side effects relates to
the dopamine-2 receptors in the brain.
It is now recognized that antipsychotic-naïve individuals
can develop involuntary movement disorders and these
are classified as spontaneous dyskinesia (SD) [8-10]. Drugs
associated with TD are chlorpromazine and other anti-
psychotic drugs and metoclopramide (MCP) [3,11,12].
Spontaneous and tardive dyskinesia are more common in
older ages [13,14]. The incidence of spontaneous dyskin-
esia by age and sex has not been well studied. For drug-
related dyskinesia, the incidence may be related to the
increased use of neuroleptic drugs or MCP in older indi-
viduals. For example, MCP is used to treat gastrointestinal
problems associated with diabetes mellitis. In addition,
there is a strong correlation between age and cumulative
antipsychotic exposure.
In addition to MCP and antipsychotic drugs, diabetes
mellitus has been reported to be a risk factor for TD
[15,16], although there remains some uncertainty about
the causal mechanisms of this link [17]. Diabetes may be
associated with TD because MCP has been used to treat
gastro-paresis, a consequence of severe diabetes [18,19].
Other studies have suggested an independent association
between dyskinesia and diseases such as diabetes, schi-
zophrenia, and other psychoses in the absence of inges-
tion of MCP or antipsychotic [8-10]. While the focus in
this paper is on first-generation antipsychotics and dys-
kinesia, newer second-generation antipsychotics (e.g.,
clozapine and olanzapine) have been shown to cause
problems related to metabolic syndrome, thereby con-
tributing to obesity and type 2 diabetes mellitus [20].
Prevalence and incidence rates of TD and SD have
varied widely because of differences in patient character-
istics and methodological approaches. Most studies have
used cross-sectional (or prevalence) data on patients with
schizophrenia or other psychoses, but some have used
retrospective cohort data and a small number have used
prospective cohort data [3,4,8-10,21,22]. The purpose of
the current study was to determine the incidence of all
types of dyskinesia in general population and also to
examine its connection to underlying medical conditions
such as diabetes independent of antipsychotic medication
use, and in association with use of first-generation anti-
psychotic drugs and metoclopramide.
Methods
Study population
A retrospective cohort study was conducted using data
from the Deseret Mutual Benefit Administrators (DMBA),
a health insurance company for employees of the Church
of Jesus Christ of Latter-day Saints. The company was
established in 1970 to provide health insurance andretirement income to church employees and their families.
There are about 80,000 individuals covered by the DMBA
each year. There is little employee turnover, estimated at
less than 5% per year [23]. The majority of turnover oc-
curred among young adults who lose eligibility for cover-
age under their parents’ health insurance plan and
individuals who become eligible for Medicare. Member-
ship in the church is a requirement for employment, with
two exceptions; employees of Deseret management com-
panies and commercial enterprises do not need to be
members of the church (roughly 11-13% of enrollees).
The majority (70%) of enrollees work in Utah. Approxi-
mately 45.6% of enrollees are employed in the Latter-day
Saint Church education system principally as teachers;
21.1% of enrollees are maintenance and custodial workers;
and the remaining 33.3% work in other capacities for the
Church. There is a relatively low prevalence of tobacco
smoking, alcohol consumption, and illicit drug use among
members of the database due to the proscription of these
substances by the Latter-day Saint Church [24].
Employees, spouses and dependent children are in-
cluded in the database. During the study period 2001
through 2010, there were 144,308 distinct individuals in
the database and they accrued 798,542 person-years of
observation. Mean age increased from 34.7 (SD = 23.3) in
2001 to 37.1 (SD = 24.6) in 2010, with 49.9% ages 0–24,
20.6% ages 25–44, 19.0% ages 45–64, and 10.5% ages
65 years and older. The percentage of males was slightly
lower than females (49.2 vs. 50.8%). At age 65, many move
to Medicare, but purchase supplemental insurance
through DMBA. The supplemental insurance should cap-
ture all new claims for these individuals.
The database was de-identified according to Health In-
surance Portability and Accountability Act (HIPAA)
guidelines and was exempt from the need for informed
consent by the Institutional Review Board at the Univer-
sity of Utah. The current study was approved and classi-
fied as a low risk study by the Institutional Review Board.
Outcome variables
The primary outcome variables of interest were tardive
dyskinesia (TD) and spontaneous dyskinesia or dystonia
(SD).
Tardive dyskinesia and SD were identified by any one
(or a combination) of the International Classification of
Diseases, 9th Revision (ICD-9), codes 333.81, 333.82,
333.83, 333.84, 333.85 (a new code introduced October
1, 2006), and 333.89 being present on a paid DMBA
claim as a reason for the enrollee’s office visit [25]. If a
claim was filed for use of any antipsychotic drug and/or
MCP prior to the claim for dyskinesia, the disease was
classified as TD, otherwise as SD. The ICD coding sys-
tem did not include a separate code for a dyskinesia that
appeared after exposure to medication until October
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this study we reviewed each individual’s prescription
drug use and only included those with prior history of
antipsychotic or MCP use before the diagnosis of any
type of dyskinesia. We then combined those with prior
drug exposure with any of the dyskinesia codes with the
new 333.85 code. Among 263 patients with one of the
ICD-9 codes for a specific dyskinesia, 34 were classified
as TD and 229 as SD.
In this study, we defined a person as having “probable
TD” or “probable SD” if he/she had one or more claims
involving the above ICD-9 codes (and met the medica-
tion use criteria above). We also present results with a
stricter definition of TD and SD, wherein at least two
claims were paid for the dyskinesia within a 12 month
time period. Our reasoning was that a physician may
make a tentative diagnosis based on a single visit by a
patient with a complaint of unexplained involuntary
muscular movements. If symptoms persisted, then this
would cause the individual to make a second visit, and
so two visits within one year with the same diagnosis
would be more likely to identify a patient with actual
disease. This definition better fits the Schooler-Kane cri-
teria for the diagnosis of TD or SD that only accepts a
diagnosis based on two separate examinations three
months apart [26]. The confidentiality agreement that
covers our use of the DMBA database does not allow us
to characterize physicians by their medical specialty so it
was not possible to identify how many diagnoses were
made by a primary care physician and how many were
made by a neurologist, or psychiatrist.
Antipsychotic
An antipsychotic is any drug used to treat psychosis, par-
ticularly schizophrenia. For the purpose of this study, we re-
stricted our analysis to the classic antipsychotic drugs,
which were introduced into psychiatric practice in the
1950’s and were still in use between 2001 and 2010. Clas-
sical antipsychotic drugs have a proven or suspected associ-
ation with TD. Antipsychotic drugs were chosen from lists
of classic drugs used during 2001 through 2010 [27,28]:
amitriptyline, chlorpromazine, compazine, etrafon, fluphen-
azine, haldol, haloperidol, halperon, kenazine, loxapine,
loxitane, maxolon, melacen, mellaril, mesoridazine besyl-
ate, millazine, moban, navane, orap, ormazine, perphena-
zine, prochlorperazine, serentil, stalizin, thioridazine, triavil,
trifluoperazine, trilafon, trifluoperazine. Use of these drugs
was identified using corresponding National Drug Codes
(NDCs), and ranged in dose from 1 mg to 200 mg. In a
study involving psychiatric patients over 45 years of age,
use of antipsychotic drugs greater than 30 days was con-
sidered to be associated with higher risk for TD [29]. Anti-
psychotic drug use had to precede TD in order to be
considered a cause of the disease.Metoclopramide
Researchers have recommended that MCP should not be
used for more than 3 months in order to avoid the risk
of TD [26]. More recently the Food and Drug Adminis-
tration (FDA) has recommended that MCP be used for
no longer than 30 days to avoid the risk of TD [30]. Both
oral and non-oral MCP products are available in the US,
each with a unique drug code. The non-oral MCP prod-
ucts include injections and topical preparations. Drug
lists were queried to find the oral and injection products
of MCP. The National Drug Code (NDC), and identifica-
tion number issued by the FDA, is the reference used in
the DMBA database. The following national drug
current MCP products, as well as products withdrawn
during the analysis period, were used in the study:
metoclopramide, metoclopramine, metozolv, myclopramide,
octamide, raglan. These medications ranged in dose from
5 mg to 10 mg. Topical MCP was not used in assessing
MCP exposure because transdermal absorption is low
[31,32].
Diabetes diagnosis
Diabetics are at increased risk for gastroparesis and
MCP has been the preferred drug to treat this condition
[19]. Both type I and II diabetes mellitus were included
in the study. The ICD-9 code 250 was used to identify a
case. Hyperglycemia NOS (ICD-9 codes 790.6), neonatal
diabetes mellitus (775.1), nonclinical diabetes (790.2),
and diabetes complicating pregnancy, childbirth, or the
puerperium (648.0) were excluded. Diabetes was only as-
sociated with dyskinesia if it was diagnosed prior to TD
or SD.
Psychoses
Individuals with psychoses may be at increased risk of
spontaneous movement disorders, even without a his-
tory of MCP or antipsychotic drug use [6,7,33,34]. The
ICD-9 code 295 was used to identify persons with
schizophrenia, and codes 296–299 were used to identify
other psychoses: affective psychoses (ICD-9 = 296), para-
noid states (ICD-9 = 297), other nonorganic psychoses
(ICD-9 = 298), and psychoses with origin specific to
childhood (ICD-9 = 299). Schizophrenia and other
psychoses were only associated with dyskinesia if they
were diagnosed prior to TD or SD.
Statistical techniques
Counts, percentages, and incidence rates were used to de-
scribe the data. The incidence rates reflected new cases in
the numerator. A table was constructed to calculate the
time under observation of each of the individuals included
in this study since there were loses and additions of indi-
viduals during the 10 years of the study. Each person’s
contribution of observable time was calculated based on
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nominator was obtained. We also calculate person-time
for those with diabetes, schizophrenia or other psychoses.
This allowed us to estimate incidence rates for each of
these conditions. Rate ratios were used to measure the as-
sociation between dyskinesia and the selected diseases and
types of medications used. Ninety-five percent confidence
intervals were calculated for the rates and rate ratios. Rate
ratios were considered significant if the confidence inter-
val did not overlap 1. Statistical significance was based on
the two-sided hypothesis and a P value of 0.05 or less.
Analyses were performed using SAS 9.3 (SAS Institute
Inc., Carry, NC, 2002–2010).
Results
During 2001 through 2010, 263 individuals in this popu-
lation had a first time diagnosis of dyskinesia. The distri-
bution of ICD-9 codes used to define TD and SD are
presented in Table 1. The distribution of codes differed
between TD and SD, with those who developed TD pre-
senting with a greater percentage of orofacial or sub-
acute dyskinesia and those with SD experiencing more
blepharospasm. For TD and SD combined, the distribu-
tion of codes did not significantly differ between men
and women, but varied by age (Figure 1).
The number of enrollees prescribed antipsychotic
drugs only, MCP only, or both are shown in Table 2.
The table also shows the number with an ICD-9 claim
(333.81-333.89) following prescribed medication. The right




Description No. % No.a %a
Tardive dyskinesia – drug related…
333.81 Blepharospasm 11 32.4 8 32.0
333.82/
333.85
Orofacial or subacute dyskinesia 11 32.4 8 32.0
333.83 Spasmodic torticollis 10 29.4 7 28.0
333.89 Other 2 5.8 2 8.0
34 25
Spontaneous dyskinesia – non-drug
related …
333.81 Blepharospasm 105 45.8 67 45.6
333.82 Orofacial or subacute dyskinesia 34 14.8 26 17.7
333.83 Spasmodic torticollis 77 33.6 48 32.6
333.84 Organic writers’ cramp 3 1.3 2 1.4
333.89 Other 10 4.4 4 2.7
229 147
Source: Deseret Mutual Benefit Administrators, 2001–2010.
aTwo or more diagnoses within a 12 month time period.more diagnoses within a 12 month time period. The rate
of TD is lowest for those treated with antipsychotic drugs
only and greatest for those treated with both types of medi-
cations prior to their diagnoses. Prior antipsychotic and/or
MCP use tended to be at least three months prior to diag-
nosis. Results are similar under the case requirement of
two or more diagnoses within a 12 month time period.
Incidence rates of probable TD and SD, along with in-
cidence rates based on the more restricted definition are
shown in Table 3. The rates of SD are about 6 to 7 times
greater than for TD. The incidence rates of TD and SD
increased with age (Figure 2) and were greater for fe-
males (Figure 3). There were no statistically significant
changes in the incidence rates of TD or SD across calen-
dar years.
Positive associations existed between selected diseases
(diabetes, schizophrenia, and other psychoses) and the
incidence rate of probable TD (Table 4). Those with dia-
betes or psychoses had almost a 3-fold greater risk of
TD than those without either of these diseases. Persons
with schizophrenia had 31.2 times increased risk of TD
than those without the disease (4.4 times the risk for
those with no prior use of an antipsychotic and/or
metoclopramide). Positive associations also existed be-
tween the selected diseases and the incidence rate of
probable SD. Diabetes had a slightly higher association
with the incidence rate of SD than with TD, and psych-
oses had a smaller association with the incidence rate of
SD than with TD, albeit statistically significant. Persons
with schizophrenia had 4.4 times greater risk of SD than
those without the disease, a much smaller rate ratio than
in the case of TD.
Discussion
We believe this is the first report of the incidence of
spontaneous and tardive dyskinesia in a general po-
pulation. The strengths of the study include a stable
population, a ten year period of observation, an accur-
ate measurement of the population at risk, the ability
to identify prior diseases from the same database, the
ability to link to pharmacy records, stable and expe-
rienced physician providers, and a low percentage of
tobacco smokers.
Others have made estimates of the incidence of TD.
Wiholm and colleagues identified 11 new cases of TD
(1 in 2000–2800 treatment-years) in the Swedish popula-
tion over a five year time period and linked these to use
of MCP using reports from an adverse drug reaction
reporting system that relied on self-reports by physicians
[9]. Their study did not provide information about the
incidence of SD, but the authors suggested there was an
association between long term use of MCP and the de-
velopment of TD, because many of those with TD had












0-24 25-44 45-65 65+
Blepharospasm Orofacial or subacute dyskinesia Spasmodic torticollis Organic writers’ cramp Other
Figure 1 Distribution of ICD-9 classifications of dyskinesia according to age group. Source: Deseret Mutual Benefit Administrators,
2001–2010. Note: Based on TD and SD combined. The distribution significantly differed by age group, P < 0.0001.
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million prescriptions of MCP in the United Kingdom,
also based on an adverse drug reaction reporting system
[35]. The incidence of dystonia and dyskinesia was 1.8
times greater in females than males.
Glazer and colleagues estimated the incidence of TD
among a group of patients with schizophrenia confined
to a large residential psychiatric hospital after five years
of antipsychotic exposure (32%), 15 years of exposure
(57%), and 25 years of exposure (68%) [36]. The study did
not report information about dyskinesia among those with-
out schizophrenia, nor was information available about dys-
kinesia among those not exposed to antipsychotic drugs.
Inada and colleagues calculated an annual incidence rate of
TD among psychiatric patients from 11 facilities in Japan
[14]. The study found an annual incidence rate of TD to be
3.7%. Dyskinesia was not reported according to anti-
psychotic status. None of these studies were controlled for
tobacco smoking, which has been suggested to be an inde-
pendent cause of dyskinesia [37,38].
These studies are not directly comparable with our
study because they tended to focus on individuals
continuously exposed to MCP or high doses of anti-
psychotic drugs among individuals with schizophrenia.
Very few in our study likely had long-term exposure to
these medications. In addition, their populations in-
volved psychiatric patients severe enough to require
long-term institutionalization, whereas none of those
with schizophrenia in our population had disease severe
enough to be institutionalized. Finally, our population
likely had far fewer smokers because tobacco smoking
and alcohol drinking are proscribed by the Latter-day
Saint Church [24].Most other studies have measured the prevalence, not
the incidence, of TD. The initial studies measured the
prevalence of TD among those committed to psychiatric
hospitals for schizophrenia or among patients in ex-
tended care facilities with various psychoses [4]. A study
by Ganzini and colleagues in 1993 was the first to esti-
mate the prevalence of TD among non-psychiatric out-
patients treated for three months or longer with MCP
and who received their medical care through a Veterans
hospital [10]. The high prevalence of TD among those
exposed to MCP compared with the control group (29%
versus 16%) led the authors to suggest that TD and SD
were common conditions in the general population, and
that both drug-induced and spontaneous dystonias were
much more serious medical problem than had previ-
ously been recognized. A study by Sewell and colleagues,
who based their study of TD on veterans receiving med-
ical care at the San Diego VA Medical Center, came to a
similar conclusion [39].
Our study findings differ from those reported in these
two earlier papers. Specifically, the incidence rates
presented in the current study do not support preva-
lence rates of 12% to 29% for SD or TD in the general
population. A crude estimation of our period prevalence
rates based on about 80,000 individuals under observa-
tion during each of the 10 years of the study, and cumu-
lating all our cases with two or more visits yields a
10 year period prevalence of 1.8 per 1,000 individuals.
For all those using the antipsychotic drugs and MCP, we
have a prevalence of 6.1 per 1000. The crude estimate of
period prevalence will be higher than the actual estimate
of point prevalence since it does not allow for individ-
uals with dyskinesia to leave the population during the


































Antipsychotic only 1,942 0 9 4.6 1.6-7.7 0 5 2.6 0.3-4.8
Metoclopramide only 2,352 3 17 8.5 4.8-12.2 3 13 6.8 3.5-10.1
Both Medications 333 3 2 15.0 2.0-28.1 2 2 12.0 0.3-23.7
Source: Deseret Mutual Benefit Administrators, 2001–2010.




























Tardive dyskinesia 4.3 2.8-5.7 3.1 1.9-4.4
Spontaneous dyskinesia 28.7 25.0-32.4 18.4 15.4-21.4
Source: Deseret Mutual Benefit Administrators, 2001–2010.
aTwo or more diagnoses within a 12 month time period.
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found a prevalence of TD of 8%, based on psychiatric
patients from 11-facilities in Japan [14].
The reason for such a large discrepancy between these
rates is not readily apparent. Both the studies used a more
precise diagnostic measure for dyskinesia, but only applied
it once, thus including individuals who did not meet the
Schooler-Kane criteria. In the study by Ganzini and col-
leagues, 19% of the control group also was reported to
have undiagnosed Parkinson’s disease [12]. Selection bias
is a likely explanation for the disparity in the results and
was not considered by the authors of these studies. Specif-
ically, overestimation of the true association between anti-
psychotic drug use or MCP and dyskinesia will be greater
in studies involving psychiatric patients than for the gen-
eral population because the association will be evaluated
more rigorously in the patient population.
Our findings provide evidence for an independent as-




















Figure 2 Incidence of Tardive Dyskinesia (TD) and Spontaneous Dysk
Administrators, 2001–2010.(diabetes mellitus, psychoses, and especially schizophre-
nia). This is consistent with previous studies examining
the association between these health conditions and TD
[15,16], as well as with SD where antipsychotic drugs
were not used [8-10]. The greater than 30-fold increased
risk of TD among those with schizophrenia (and expos-
ure to an antipsychotic drug) compared with those with-
out schizophrenia is congruent with what many others
have reported previously. The estimate is much higher
than that reported by Morgenstern and colleagues [4].
We do not have an explanation for this difference. Our
findings also provide evidence for an independent asso-
ciation between each of the selected health conditions
and SD. The finding of a 4-fold increased risk of spon-
taneous dyskinesia among persons with schizophrenia
(but no exposure to an antipsychotic drug) compared
with those without schizophrenia may be a result of the
underlying disease, as suggested by others [8-10].
Our study reports data from a defined population, all
with health insurance, and coverage for prescription
medication. We ascertained the incidence of the SD and
TD using this system. There were no changes in the med-
ical coverage of this population during the 10 years of the
study that could bias our findings. Our definition of a new
case of SD or TD meets minimal standards for such a
diagnosis, two episodes separated by up to a year. Because
of the nature of the data base individual cases could not
be confirmed by an independent examination. The most
likely outcome of an independent examination using more45-64 65+
Probable SD
inesia (SD) according to age. Source: Deseret Mutual Benefit
Table 4 Rate ratio of Tardive Dyskinesia (TD)
Spontaneous Dyskinesia (SD) according to diabetes,
Schizophrenia, and other Psychoses









Yes 66758 7 2.8 1.2-6.5 37 3.0 2.1-4.3
No 731784 27 135
Schizophrenia
Yes 1597 2 31.2 7.5-130.1 2 4.4 1.1-17.7
No 796945 32 227
Psychosesc
Yes 59252 6 2.7 1.1-6.5 26 1.6 1.1-2.4
No 739290 28 203
Source: Deseret Mutual Benefit Administrators, 2001–2010.
Diabetes (ICD-9-CM codes 250- < 251) only counted if it occurred prior to TD.
Psychosis (ICD-9-CM codes 296- < 300) only counted if it occurred prior to TD.
Schizophrenia (ICD-9-CM codes 295- < 296) only counted if it occurred prior
to TD.
aClaim filed with an ICD-9 code 333.81-333.89, with prior use of an
antipsychotic and/or metoclopramide.
bClaim filed with an ICD-9 code 333.81-333.89, with no prior use of an
antipsychotic and/or metoclopramide.
c5 of the 6 counts for probable TD and 24 or the 26 for probable SD involved




















Probable TD Probable SD
Figure 3 Incidence of Tardive Dyskinesia (TD) and Spontaneous Dyskinesia (SD) according to sex. Source: Deseret Mutual Benefit
Administrators, 2001–2010.
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untary Movement Scale (AIMS) would be to eliminate
some of the individuals who we classified as having SD or
TD, and lower the incidence rates. For this reason we con-
sider the incidence rates we report to likely overestimate
the true incidence of SD or TD in any general population.
Although the results of this study are important, they
should be interpreted with some caution. The study is lim-
ited in that the information was obtained purely from an
insurance database, and not by clinical evaluations. Exam-
ination for and documentation of dyskinesia may have
been influenced by the fact that the subject was taking
antipsychotic drugs. However, selection bias is likely to be
much smaller in our study involving the general popula-
tion than in a select group of psychiatric patients, espe-
cially if they were known to have long-term exposure to
antipsychotic drugs or MCP. In addition, the nature and
distribution of the movement disorder may not have been
accurately documented unless the subject was examined
by a neurologist, or ideally, a movement disorders special-
ist. Finally, the data began in 2001 such that we were
unable to determine the duration of medication use. Ana-
lyses were based on any prior antipsychotic or MCP medi-
cation use, as recorded in the database.
Conclusion
The incidence of spontaneous and tardive dyskinesia is rare
in a large, generally non-smoking population. We were
able to confirm estimates by others that diabetes mellitis is
associated with increased risk of spontaneous dyskinesia. A
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http://www.biomedcentral.com/1471-244X/13/152higher proportion of those with spontaneous dyskinesia
present with spasm of the eyelid muscles (blepharospasm)
compared to those with tardive dyskinesia who present
with orofacial muscular problems.
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